Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.

Genzyme Corp. (Sanofi Genzyme) has disclosed sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, among others.

IN Jervis's introductory study, and in subsequent case reports of phenylketonuria (phenylpyruvic oligophrenia), a blonde hair colour and a fair skin have been noted in the large majority of the ...

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Introduction to Newborn Screening InstrumentsNewborn screening is a critical medical process that involves testing newborns for certain genetic, metabolic, and congenital conditions. The objective is ...

Melissa Russell tells PEOPLE that while daughter Leah's peers are going off to college and starting their own lives, she ...

Under Emirates Health Services (EHS) theme "Future Health Now", EHS is participating in the 50th edition of Arab Health 2025, ...

Kiesel was a political commentator on KOSU’s weekly radio program and podcast This Week in Oklahoma Politics for 13 years.

Phenylketonuria (PKU) is a genetic metabolic disorder that increases levels of the essential amino acid known as phenylalanine in the blood. People with PKU are unable to metabolize phenylalanine ...